Health Care: Drugs

Novogen Ltd (NVGN: NASDAQ)

$3.21 -0.054 | -1.65%
09/16/14 - 03:50 PM ET
Company Profile
Price and Volume
Recent Price 3.26
52 Week High 6.84
52 Week Low 2.72
Avg. Daily Vol. (Mil) 0.02
Beta (3 year) -0.75
Share Related Items
Mkt Cap (Mil) 21.09
Shares Out (Mil) 6.46
Float (Mil) 0.00
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio 0.00
Financial Strength
Quick Ratio 1.60
Current Ratio 1.60
LT Debt/ Equity 0.00
Total Debt / Equity 0.74
Valuation Ratios
Price Earnings n.a.
Price/Sales 13.49
Price/Book 4.93
Price/Cash Flow -50.60
Per Share Data
Earnings -20.85
Sales 0.24
Book Value 0.66
Cash Flow -0.06
Business Summary
Novogen Ltd is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose.
General Information
16-20 Edgeworth David Avenue
Level 1
Sydney, NS 2077
www.novogen.com
Industry : Drugs
Sector: Health Care
Employees: 5
CEO: Dr. Graham E. Kelly
Short Interest
Current Month (Mil) 0.11
Previous Month (Mil) 0.16
Short Interest Ratio (Days) 9.90
Management Effectiveness
Return on Equity n.a.
Return on Assets 0.00
Return on Investments n.a.
Profitability
Gross Margin n.a.
EBIT Margin n.a.
Profit Margin -46.60

Portfolios with NVGN

Latest NVGN Headlines from TheStreet

More Financial News for NVGN

Press Releases for NVGN

See All Press Releases

Partner Headlines for NVGN

brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter